Pfizer (NYSE:PFE) is closing in on a potential $7.3 billion takeover of weight-loss drug maker (NASDAQ:MTSR) Metsera, the Financial Times reported on Sunday.
The U.S. pharma giant looks to buy New York City-based Metsera for $47.50 per share in cash, with an additional $22.50 per share contingent on the achievement of certain performance milestones, the report said, adding that the announcement could come as early as Monday, unless deal talks fall through.
Talks to acquire Metsera (NASDAQ:MTSR) come just months after the biotech firm’s blockbuster debut on Nasdaq.
The $47.50-per-share offer reflects a roughly 42.5% premium over Metsera’s Friday closing price of $33.32, which pegged its market value at about $3.5 billion.
